The American Journal of Managed Care

FDA Approves Monthly KwikPen Option for Tirzepatide in Chronic Weight Management

The FDA has approved a label expansion for tirzepatide (Zepbound; Eli Lilly), allowing use of a 4-dose, single-patient-use KwikPen that delivers a full month of treatment in 1 device for chronic weight management, the manufacturer announced today. 1
Hosted on MSN

Vials vs Pens: Why India’s Weight Loss Journey May Lean on Mounjaro’s KwikPen

Approved by the CDSCO, in a revolutionary move, Mounjaro is now available in India in the KwikPen format. This means that it comes as a pre-filled, multi-dose, single patient use pen that stands in sharp competition as well as contrast against the ...
Nasdaq

Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®

INDIANAPOLIS, Jan. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly insulin by introducing lower-priced versions of Humalog® Mix75/25 ...
FiercePharma

U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen®

INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Humalog ® 200 units/mL KwikPen ® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting ...